Market
Which primary cancer types will the Russian mRNA cancer vaccine target by end of 2025?
2
Resolution / Starting Odds
Lung cancer • 25%
Breast cancer • 25%
Prostate cancer • 25%
Other types • 25%
Official statements from the Russian Ministry of Health or major news outlets
Story
Russia Develops Free mRNA Cancer Vaccine, Personalized for Patients, Launching in Early 2025 at 300,000 Rubles per Dose
Dec 18, 2024, 12:17 AM
Russia has announced the development of a personalized mRNA cancer vaccine, which will be distributed free of charge to patients starting in early 2025. The vaccine, designed to treat cancer rather than prevent it, will be tailored to individual patients based on their specific cancer types. Andrey Kaprin, the chief oncologist at the Ministry of Health, stated that while the vaccine's production cost is approximately 300,000 rubles per dose, it will be provided to patients at no cost. This initiative is part of Russia's broader efforts to enhance healthcare access and innovation in cancer treatment.
View original story
Similar markets
Breast Cancer • 25%
Other • 25%
Colon Cancer • 25%
Lung Cancer • 25%
Melanoma • 25%
Kidney Cancer • 25%
Gastrointestinal Cancer • 25%
Lung Cancer • 25%
50,001 to 100,000 • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%
More than 100,000 • 25%
Above 90% efficacy • 25%
70-79% efficacy • 25%
Below 70% efficacy • 25%
80-90% efficacy • 25%
Trials delayed • 25%
Successful with no major issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
WHO Recognition • 25%
EU Approval • 25%
U.S. FDA Approval • 25%
No International Recognition • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Breast Cancer • 25%
WHO Approval • 25%
No Major Approval • 25%
US FDA Approval • 25%
EU Approval • 25%